Close Menu

NEW YORK (GenomeWeb) — OpGen today priced a public offering of 9 million shares of its common stock at $.60 per share, giving the planned transaction a $5.4 million value.

The Gaithersburg, Maryland-based company said that it has also granted the underwriters of the offering a 45-day option to buy an additional 1.35 million shares to cover overallotments. Aegis Capital acted as the sole bookrunner for the offering, which is expected to close around March 28.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Researchers find that many cancer drugs in development don't work quite how their developers thought they did, as Discover's D-brief blog reports.

CBS This Morning highlights recent Medicare fraud involving offers of genetic testing.

Mariya Gabriel, a Bulgarian politician, is to be the next European Union research commissioner, according to Science.

In Science this week: a survey indicates that US adults are more likely to support the agricultural use of gene drives if they target non-native species and if they are limited, and more.

Sep
16
Sponsored by
ArcherDX

This webinar will discuss a next-generation sequencing approach for detecting genomic mutations in hematologic maglignancies.

Sep
18
Sponsored by
Bionano Genomics

This webinar will outline how a team at Radboud University Medical Center is assessing ultra-long read optical mapping on the Bionano Saphyr system to replace classical cytogenetics approaches in routine testing and for the discovery of novel structural variants with potential scientific, prognostic, or therapeutic value that are missed by standard approaches.

Sep
25
Sponsored by
HalioDx

CAR T-cell therapy is an innovative form of immunotherapy that is finding increasing use for the management of blood cancers. 

Oct
02
Sponsored by
10x Genomics

This webinar will discuss a study that used spatial transcriptomics to gain insight into the molecular mechanisms of amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease.